How A Merck Attorney’s Lies Torpedoed A $200M Patent Verdict

By Ryan Davis | June 10, 2016, 6:27 PM EDT

When officials from Merck & Co. Inc. and Pharmasset Inc. held a conference call on March 17, 2004, to discuss possible collaborations, Merck in-house patent prosecutor Philippe Durette assured Pharmasset that details he learned about the company’s “crown jewel” hepatitis C research would be kept confidential.

After Pharmasset officials discussed the structure of a promising compound for treating the disease, Durette told them that it “seems quite related to things that I’m involved with” and that he needed to have a conversation with his supervisor. He...
To view the full article, register now.